Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S.

Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

2.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

3.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
4.
5.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211
6.

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR.

Pharmacoeconomics. 2013 Jul;31(7):589-604. doi: 10.1007/s40273-013-0035-8.

7.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.

Thromb Haemost. 2012 Oct;108(4):672-82. Epub 2012 Aug 17.

PMID:
22898892
8.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM.

Thromb Haemost. 2011 May;105(5):908-19. doi: 10.1160/TH11-02-0089. Epub 2011 Mar 22.

PMID:
21431243
9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

10.

Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.

Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP.

S Afr Med J. 2013 Feb 15;103(4):241-5. doi: 10.7196/samj.6471.

PMID:
23547700
11.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR.

Heart. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646.

12.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
13.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

14.

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

McKeage K.

Pharmacoeconomics. 2012 Sep 1;30(9):841-55. doi: 10.2165/11209130-000000000-00000. Review.

PMID:
22734683
15.
16.

Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.

Singh SM, Micieli A, Wijeysundera HC.

Circulation. 2013 Jun 18;127(24):2414-23. doi: 10.1161/CIRCULATIONAHA.112.000920. Epub 2013 May 22.

17.

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

Langkilde LK, Bergholdt Asmussen M, Overgaard M.

J Med Econ. 2012;15(4):695-703. doi: 10.3111/13696998.2012.673525. Epub 2012 Mar 22.

PMID:
22397590
18.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

19.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
20.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.

Items per page

Supplemental Content

Write to the Help Desk